Key Highlights

  • Loss per share was USD 0.29 against an estimate of a USD 0.35 loss.
  • Net loss was USD 31.14 million, compared with USD 47.71 million.
  • Research and development expenses were USD 25.93 million, compared with USD 44.93 million.
  • Cash and cash equivalents were USD 76.99 million at September 30, 2026.

Larimar Therapeutics (NASDAQ:LRMR) reported a net loss of USD 31.14 million for the third quarter of 2026, compared with USD 47.71 million in the prior-year quarter. Net loss per share of common stock, basic and diluted, was USD 0.29, against an estimate of a USD 0.35 loss.

For the nine months ended September 30, 2026, the net loss was USD 93.53 million, compared with USD 103.18 million, and net loss per share of common stock was USD 0.90.

Operating Expenses

Research and development expenses were USD 25.93 million, compared with USD 44.93 million, and general and administrative expenses were USD 6.54 million, compared with USD 4.57 million. Total operating expenses and the loss from operations were USD 32.46 million, compared with USD 49.50 million.

Other income, net, was USD 1.33 million, compared with USD 1.79 million. The net loss attributable to common stock was USD 29.71 million, and USD 1.43 million of the net loss was allocated to Series A Preferred. Net loss per share of Series A Preferred was USD 2.85.

Nine-Month Results

For the nine months, Research and Development expenses were USD 78.96 million, compared with USD 94.85 million, and general and administrative expenses were USD 18.98 million, compared with USD 13.63 million. Total operating expenses were USD 97.93 million, compared with USD 108.48 million. Other income, net, was USD 4.40 million, compared with USD 5.30 million.

Liquidity and Financing

Cash and cash equivalents were USD 76.99 million at September 30, 2026, compared with USD 85.41 million at December 31, 2025, and marketable securities were USD 51.67 million, compared with USD 51.44 million.

The filing states that in February 2026 the company completed an underwritten public offering of common stock raising net proceeds of approximately USD 107.6 million, and that in July 2025 it completed an offering raising approximately USD 65.0 million. In the third quarter of 2026, the company sold 751,682 shares under its ATM agreement with Guggenheim Securities for net proceeds of approximately USD 3.1 million, and USD 96.9 million remained available for sale.

The filing states that the company anticipates its cash, cash equivalents and marketable securities fund forecasted operating expenses and Capital Expenditure requirements into the late second quarter of 2027, and that these resources are not sufficient to fund planned operations for at least one year from the date the financial statements are issued.

Weighted average shares of common stock outstanding were 104,211,155 for the quarter and 99,355,705 for the nine months, and weighted average Series A Preferred Shares outstanding were 500,000 for the quarter and 480,769 for the nine months. The filing notes that the weighted average number of Series A Preferred shares reflects only the period of time that the class has been newly designated and issued. For the nine months, USD 4.32 million of the net loss was allocated to Series A Preferred, and net loss per share of Series A Preferred was USD 8.98.

Larimar Therapeutics Q3 2026 Earnings: Key Takeaways

Larimar Therapeutics reported a third quarter 2026 net loss of USD 31.14 million and a loss per share of USD 0.29. Cash and cash equivalents were USD 76.99 million at September 30, 2026.